Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227324 · ClinicalTrials.gov registry record
Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)
A clinical trial of Cancer and Cannabis Use, sponsored by HealthPartners Institute.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT07227324: Recruiting study of Cancer and Cannabis Use, sponsored by HealthPartners Institute.
NCT07227324 is a study of Cancer and Cannabis Use that is actively recruiting participants, run by HealthPartners Institute. The registered enrollment target is 1,000 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227324, a study of Cancer and Cannabis Use, is actively recruiting participants, sponsored by HealthPartners Institute.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Through partnership with Ontracka, the HealthPartners Institute Cancer Research Center created a secure and compliant app-based technology with the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in supportive care medications such as opioids and antiemetics. By joining this registry, patients will have access to expert cannabis education, dosing recommendations, and easy symptom tracking. Patients with cancer and their oncology clinicians can utilize this reliable, cancer-specific data to help them make informed decisions together about how cannabis could be incorporated into a treatment plan. To learn more and sign up, visit https://study.ontracka.com/cannabiscurious
Primary Outcome
Assess adherence to CURIOUS platform by determining the percentage of consented patients who access the app/survey at least once per month during the first 90 days.
Conditions Studied
Study Locations (1)
Minnesota
- HealthPartners Institute Cancer Research Center - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2028-04 |
What NCT07227324 shows while recruiting
NCT07227324 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07227324 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07227324 about?
NCT07227324 is a clinical study titled "Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)". Through partnership with Ontracka, the HealthPartners Institute Cancer Research Center created a secure and compliant app-based technology with the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in ...
What is the current status of trial NCT07227324?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-08-26. Estimated completion is 2028-04.
What conditions does trial NCT07227324 study?
This clinical trial studies the following conditions: Cancer, Cannabis Use.
Who is sponsoring clinical trial NCT07227324?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227324 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07227324's enrollment target sits among peer trials
1,000 80th of 615 higher than 531 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI